Albert Y. Lau

Albert Y. Lau

Auto-generated profile, based on publicly available information

Albert Y. Lau

Department of Biophysics and Biophysical Chemistry, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 July 2004 in Science
Verified
Journal Article
Closed access
PDF file
NRNiroshan Ramachandran
Niroshan Ramachandran
EHEugenie Hainsworth
Eugenie Hainsworth
BBBhupinder Bhullar
Bhupinder Bhullar
SESamuel Eisenstein
Samuel Eisenstein
BRBenjamin Rosen
Benjamin Rosen
JLJoshua LaBaer
Joshua LaBaer
Protein microarrays provide a powerful tool for the study of protein function. However, they are not widely used, in part because of the challenges in producing proteins to spot on the arrays. We generated protein microarrays by printing complementary DNAs onto glass slides and then translating target proteins with mammalian reticulocyte lysate. Epitope tags fused to the proteins allowed them to be immobilized in situ. This obviated the need to purify proteins, avoided protein stability problems during storage, and captured sufficient protein for functional studies. We used the technology to map pairwise interactions among 29 human DNA replication initiation proteins, recapitulate the regulation of Cdt1 binding to select replication proteins, and map its geminin-binding domain.

1 October 1998 in Cell
Verified
Journal Article
Closed access
ALAlbert Y. Lau
Albert Y. Lau
OSOrlando D. Schärer
Orlando D. Schärer
LSLeona Samson
Leona Samson
GVGregory L. Verdine
Gregory L. Verdine
TETom Ellenberger
Tom Ellenberger

5 December 2000 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
ALAlbert Y. Lau
Albert Y. Lau
MWMichael D. Wyatt
Michael D. Wyatt
BGBrian J. Glassner
Brian J. Glassner
LSLeona D. Samson
Leona D. Samson
TETom Ellenberger
Tom Ellenberger
The human 3-methyladenine DNA glycosylase [alkyladenine DNA glycosylase (AAG)] catalyzes the first step of base excision repair by cleaving damaged bases from DNA. Unlike other DNA glycosylases that are specific for a particular type of damaged base, AAG excises a chemically diverse selection of substrate bases damaged by alkylation or deamination. The 2.1-Å crystal structure of AAG complexed to DNA containing 1, N 6 -ethenoadenine suggests how modified bases can be distinguished from normal DNA bases in the enzyme active site. Mutational analyses of residues contacting the alkylated base in the crystal structures suggest that the shape of the damaged base, its hydrogen-bonding characteristics, and its aromaticity all contribute to the selective recognition of damage by AAG.

1 December 2003 in Journal of Biological Chemistry
Verified
Journal Article
Open access
RWR. Scott Williams
R. Scott Williams
DCDaniel I. Chasman
Daniel I. Chasman
DHD. Duong Hau
D. Duong Hau
BHBenjamin Hui
Benjamin Hui
ALAlbert Y. Lau
Albert Y. Lau
JGJ. N. Mark Glover
J. N. Mark Glover
Most cancer-associated BRCA1 mutations identified to date result in the premature translational termination of the protein, highlighting a crucial role for the C-terminal, BRCT repeat region in mediating BRCA1 tumor suppressor function. However, the molecular and genetic effects of missense mutations that map to the BRCT region remain largely unknown. Using a protease-based assay, we directly assessed the sensitivity of the folding of the BRCT domain to an extensive set of truncation and single amino acid substitutions derived from breast cancer screening programs. The protein can tolerate truncations of up to 8 amino acids, but further deletion results in drastic BRCT folding defects. This molecular phenotype can be correlated with an increased susceptibility to disease. A cross-validated computational assessment of the BRCT mutation data base suggests that as much as half of all BRCT missense mutations contribute to BRCA1 loss of function and disease through protein-destabilizing effects. The coupled use of proteolytic methods and computational predictive methods to detect mutant BRCA1 conformations at the protein level will augment the efficacy of current BRCA1 screening protocols, especially in the absence of clinical data that can be used to discriminate deleterious BRCT missense mutations from benign polymorphisms.


13 February 2011 in Nature Structural & Molecular Biology
Verified
Journal Article
Open access
PDF file
ALAlbert Y Lau
Albert Y Lau
BRBenoît Roux
Benoît Roux
Binding of a neurotransmitter to the ligand-binding domain of glutamate receptors results in conformational changes and opening of the channel. The relationship between ligand binding and activation is not clear, and now the energetics of ligand binding are dissected using computational methods. Ionotropic glutamate receptors (iGluRs) are ligand-gated ion channels that mediate most excitatory synaptic transmission in the central nervous system. The free energy of neurotransmitter binding to the ligand-binding domains (LBDs) of iGluRs is converted into useful work to drive receptor activation. We have computed the principal thermodynamic contributions from ligand docking and ligand-induced closure of LBDs for nine ligands of GluA2 using all-atom molecular dynamics free energy simulations. We have validated the results by comparison with experimentally measured apparent affinities to the isolated LBD. Features in the free energy landscapes that govern closure of LBDs are key determinants of binding free energies. An analysis of accessible LBD conformations transposed into the context of an intact GluA2 receptor revealed that the relative displacement of specific diagonal subunits in the tetrameric structure may be key to the action of partial agonists.